• In early May 2026, Darling Ingredients reported first-quarter 2026 results showing revenue of US$1,550.82 million and net income of US$134.31 million, followed by an Investor Day where management outlined three-year priorities and a Shelf Registration filing for 5,645,450 ESOP-related common shares worth about US$356.28 million.
• The company emphasized the growing contribution of its Diamond Green Diesel joint venture and projected US$4–6 billion of cash generation from 2027 to 2030 to fund debt reduction, selective acquisitions, shareholder returns, and further investments in renewable fuels and collagen.
• Next, we will examine how this return to profitability and cash generation outlook could influence Darling Ingredients' existing investment narrative.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Darling Ingredients Investment Narrative Recap

To own Darling Ingredients today, you need to believe in its rendering, collagen, and renewable fuels platform, with Diamond Green Diesel as a key earnings driver. The Q1 2026 return to profitability and management’s US$4–6 billion cash generation outlook reinforce that thesis, while high leverage and policy-sensitive renewable fuel margins remain the biggest near term risks. The recent ESOP-related shelf registration does not appear to materially change these core catalysts or risks.

The most relevant update is the Investor Day framework around stronger cash generation and deleveraging, supported by DGD’s improved contribution. That roadmap directly connects to prior catalysts tied to policy support for renewable fuels and collagen expansion, but it also reframes leverage as a central execution risk: realizing those 2027–2030 cash targets will matter for how quickly Darling can reduce debt, fund growth in Nextida, and consider richer shareholder returns.

Yet, while the recent cash generation outlook is encouraging, investors should also be aware of how regulatory uncertainty could still...

Darling Ingredients' narrative projects $7.2 billion revenue and $676.3 million earnings by 2029. This requires 5.4% yearly revenue growth and a $613.5 million earnings increase from $62.8 million today.

Uncover how Darling Ingredients' forecasts yield a $72.17 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts painted a much tougher picture, assuming only about US$6.3 billion of revenue and US$519.5 million of earnings by 2028, and arguing that higher compliance costs and regulatory scrutiny on animal based inputs could offset much of the benefit from renewable fuel policies. Their view shows how sharply opinions can differ, and how fresh data like the Q1 rebound and DGD outlook might eventually shift those expectations in very different directions.

Explore 3 other fair value estimates on Darling Ingredients - why the stock might be worth just $70.00!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Darling Ingredients research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Darling Ingredients research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Darling Ingredients' overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.